# RMHI (Peak Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Peak Pharmaceuticals, Inc. reported $102K in total assets and a net loss of $218K through September 30, 2022 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/RMHI
- Markdown: https://convexityos.com/fundamentals/RMHI.md
- SEC CIK: 0001452804
- Reporting currency: USD
- Latest filing period: December 31, 2022
- Last synced: Nov 20, 2026, 05:50 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001452804&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2022 | -- | Sep 30, 2022 |
| Operating Income | FY 2022 | -$222K | Operating profit |
| Net Income | FY 2022 | -$218K | GAAP bottom line |
| Diluted EPS | FY 2022 | -- | Split-adjusted |
| Free Cash Flow | FY 2022 | -- | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2022 | $97K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2016 | FY 2015 | FY 2014 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | -- | -- | -- | -- | -- | -- | -- | -- | $13K | $30K |
| Selling, General & Admin | -- | -- | -- | -- | -- | $24K | $24K | -- | -- | -- |
| Total Operating Expenses | $163K | $69K | $5.5K | $5.7K | $28K | $45K | -$1.09M | -- | $2.34M | $3.09M |
| **Operating Income** | -$163K | -$69K | -$5.5K | -$5.7K | -$28K | -$45K | $1.09M | -- | -$2.34M | -- |
| **EBITDA** | -- | -- | -- | -- | -- | -- | $1.11M | -- | -$2.33M | -- |
| Interest Expense | $32K | $10K | $9.5K | $8.3K | $5.6K | $1.2K | $0 | -- | $2.2K | -$697K |
| Income Tax Expense | -- | -- | -- | -- | -- | -- | $0 | -- | $0 | -- |
| **Net Income** | -$165K | -$76K | -$15K | -$14K | -$28K | -$51K | $1.16M | $1.16M | -$2.31M | -$3.76M |
| Basic EPS | -- | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -- | -- | -- | -- |
| **Diluted EPS** | -- | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -- | -- | -- | -- |
| Basic Shares Outstanding | -- | 78.4M | 78.4M | 78.4M | 78.4M | 78.4M | 78.4M | -- | 78.3M | 75.2M |
| Diluted Shares Outstanding | -- | 78.4M | 78.4M | 78.4M | 78.4M | 78.4M | 80.9M | -- | 78.3M | 75.2M |

### Income Statement (Quarterly)

| Line Item | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Total Operating Expenses | $110K | $53K | $12K | $47K | $52K | $3.7K | $17K | $43K |
| **Operating Income** | -$110K | -$53K | -$12K | -$47K | -$52K | -$3.7K | -$17K | -$43K |
| Interest Expense | $1.8K | $7.3K | $8.0K | $8.0K | $8.8K | $3.2K | $2.4K | $2.5K |
| **Net Income** | -$112K | -$60K | $8.8K | -$55K | -$59K | -$6.8K | -$19K | -$43K |
| Basic EPS | -- | -- | -- | $0.00 | $0.00 | -- | $0.00 | $0.00 |
| **Diluted EPS** | -- | -- | $0.00 | $0.00 | $0.00 | -- | $0.00 | $0.00 |
| Basic Shares Outstanding | -- | -- | -- | 78.4M | 78.4M | -- | 78.4M | 78.4M |
| Diluted Shares Outstanding | -- | -- | 82.0M | 78.4M | 78.4M | -- | 78.4M | 78.4M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $128K | $261K | $0 | $0 | $0 | $0 | $1.3K | $202K | $451K | $4.9K |
| **Cash & Short-Term Investments** | $128K | $261K | $0 | $0 | $0 | $0 | $1.3K | $202K | $451K | $4.9K |
| **Total Current Assets** | -- | -- | $408 | $527 | $2.3K | $3.0K | $1.3K | $259K | $458K | $4.9K |
| Intangible Assets | -- | -- | -- | -- | -- | $35K | $35K | $17K | -- | -- |
| **Total Non-Current Assets** | -- | -- | $0 | $0 | $0 | $0 | $0 | $22K | $33K | $0 |
| **Total Assets** | $130K | $261K | $408 | $527 | $2.3K | $3.0K | $1.3K | $281K | $491K | $4.9K |
| Accounts Payable | $225K | $214K | $163K | $157K | $153K | $163K | $83K | $43K | $44K | -- |
| Short-Term Debt | -- | -- | -- | -- | -- | -- | -- | -- | $603K | -- |
| **Total Current Liabilities** | -- | -- | $251K | $236K | $223K | $196K | $143K | $289K | $54K | $44K |
| **Total Non-Current Liabilities** | -- | -- | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $622K | $587K | $251K | $236K | $223K | $196K | $143K | $289K | $54K | $44K |
| **Total Debt (incl. Leases)** | -- | -- | -- | -- | -- | -- | -- | -- | $603K | -- |
| Common Stock | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $33K |
| Retained Earnings | -$5.35M | -$5.19M | -$5.11M | -$5.10M | -$5.08M | -$5.06M | -$5.00M | -$6.17M | -$3.86M | -$100K |
| **Total Stockholders' Equity** | -$491K | -$326K | -$250K | -$235K | -$221K | -$193K | -$141K | -$7.3K | $436K | -$39K |
| Total Equity | -$491K | -$326K | -$250K | -$235K | -$221K | -$193K | -$141K | -$7.3K | $436K | -$39K |

### Balance Sheet (Quarterly)

| Line Item | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $97K | $128K | $131K | $176K | $188K | $261K | $43K | $348 |
| **Cash & Short-Term Investments** | $97K | $128K | $131K | $176K | $188K | $261K | $43K | $348 |
| **Total Current Assets** | -- | -- | -- | -- | -- | -- | -- | $348 |
| **Total Non-Current Assets** | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Total Assets** | $102K | $130K | $134K | $180K | $193K | $261K | $43K | $348 |
| Accounts Payable | $307K | $225K | $175K | $203K | $197K | $214K | $225K | $208K |
| **Total Current Liabilities** | -- | -- | -- | -- | -- | -- | -- | $301K |
| **Total Non-Current Liabilities** | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Total Liabilities** | $706K | $622K | $565K | $620K | $579K | $587K | $362K | $301K |
| Common Stock | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K | $7.8K |
| Retained Earnings | -$5.47M | -$5.35M | -$5.29M | -$5.30M | -$5.25M | -$5.19M | -$5.18M | -$5.16M |
| **Total Stockholders' Equity** | -$603K | -$491K | -$431K | -$440K | -$386K | -$326K | -$319K | -$300K |
| Total Equity | -$603K | -$491K | -$431K | -$440K | -$386K | -$326K | -$319K | -$300K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2016 | FY 2015 | FY 2014 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$165K | -$76K | -$15K | -$14K | -$28K | -$51K | $1.16M | $1.16M | -$2.31M | -$3.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | $19K | -- | $12K | -- |
| Stock-Based Compensation | -- | -- | -- | -- | -- | $0 | -$1.30M | -- | $1.86M | $1.22M |
| Change in Payables | $21K | $8.7K | $4.6K | $1.8K | $4.4K | $81K | -- | -- | -- | -- |
| **Operating Cash Flow** | -$69K | -$14K | -$119 | -$1.7K | -$44K | -$18K | -$200K | -- | -$248K | -$933K |
| Capital Expenditure | -- | -- | -- | -- | -- | -- | $0 | -- | -$2.2K | -- |
| **Free Cash Flow** | -- | -- | -- | -- | -- | -- | -$200K | -- | -$250K | -- |
| **Investing Cash Flow** | -- | -- | -- | -- | -- | -- | $0 | -- | -$2.2K | -$35K |
| **Financing Cash Flow** | -$65K | $275K | -- | -- | $43K | $20K | -- | -- | -- | $1.42M |
| **Net Change in Cash** | -$134K | $261K | -- | -- | -- | -- | -- | -- | -- | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$112K | -$60K | $8.8K | -$55K | -$59K | -$6.8K | -$19K | -$43K |
| Change in Payables | $37K | $66K | -$36K | -$2.7K | -$6.2K | -$15K | $9.4K | $12K |
| **Operating Cash Flow** | -$31K | -$3.7K | -$9.7K | -$11K | -$44K | -$14K | -$60 | -$30 |
| **Financing Cash Flow** | -- | $0 | -$35K | $0 | -$30K | -- | -- | -- |
| **Net Change in Cash** | -$31K | -$3.7K | -- | -- | -$74K | -- | -- | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2016 | FY 2015 | FY 2014 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -861.2% |
| Return on Assets (ROA) | -126.6% | -29.1% | -3679.2% | -2655.2% | -1251.4% | -1712.7% | 89128.5% | 89128.5% | -820.3% | -765.7% |
| Current Ratio | -- | -- | 0.00x | 0.00x | 0.01x | 0.02x | 0.01x | 0.01x | 0.90x | 8.42x |
| Quick Ratio | -- | -- | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.70x | 8.29x |
| Debt to Equity | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38x |
| Operating Income Growth (YoY) | -- | -- | -- | -- | -- | -104.1% | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -- | -- | -- | -- | -- | -104.4% | -- | -- | -- | -- |
| 5Y Net Income / Share Growth | -- | -106.5% | -- | -- | -- | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Assets (ROA) | -212.6% | -126.6% | -83.5% | -77.7% | -66.3% | -29.1% | -172.2% | -16675.3% |
| Current Ratio | -- | -- | -- | -- | -- | -- | -- | 0.00x |
| Quick Ratio | -- | -- | -- | -- | -- | -- | -- | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
